208 related articles for article (PubMed ID: 37705980)
21. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
[TBL] [Abstract][Full Text] [Related]
22. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint inhibitor responses can be regulated by the gut microbiota - A systematic review.
Zeriouh M; Raskov H; Kvich L; Gögenur I; Bennedsen ALB
Neoplasia; 2023 Sep; 43():100923. PubMed ID: 37603952
[TBL] [Abstract][Full Text] [Related]
24. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
25. Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
Delaye M; Rousseau A; Mailly-Giacchetti L; Assoun S; Sokol H; Neuzillet C
Pharmacol Ther; 2023 Jul; 247():108442. PubMed ID: 37210004
[TBL] [Abstract][Full Text] [Related]
26. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
27. Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy.
Riemann D; Turzer S; Ganchev G; Schütte W; Seliger B; Möller M
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830562
[TBL] [Abstract][Full Text] [Related]
28. Gut microbial structural variation associates with immune checkpoint inhibitor response.
Liu R; Zou Y; Wang WQ; Chen JH; Zhang L; Feng J; Yin JY; Mao XY; Li Q; Luo ZY; Zhang W; Wang DM
Nat Commun; 2023 Nov; 14(1):7421. PubMed ID: 37973916
[TBL] [Abstract][Full Text] [Related]
29. An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets.
Chi P; Jiang H; Li D; Li J; Wen X; Ding Q; Chen L; Zhang X; Huang J; Ding Y
Front Immunol; 2022; 13():1012673. PubMed ID: 36569825
[TBL] [Abstract][Full Text] [Related]
30. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
31. Assessing the role of colonic and other anatomical sites uptake by [
Rizzo A; Cantale O; Mogavero A; Garetto L; Racca M; Venesio T; Anpalakhan S; Novello S; Gregorc V; Banna GL
Thorac Cancer; 2023 Aug; 14(24):2473-2483. PubMed ID: 37442801
[TBL] [Abstract][Full Text] [Related]
32. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA; Thomas AM; Bolte LA; Björk JR; de Ruijter LK; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Leeming ER; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Vijay A; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Bataille V; Hospers GAP; Spector TD; Weersma RK; Segata N
Nat Med; 2022 Mar; 28(3):535-544. PubMed ID: 35228751
[TBL] [Abstract][Full Text] [Related]
33. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
34. Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.
Liu W; Ma F; Sun B; Liu Y; Tang H; Luo J; Chen H; Luo Z
Front Immunol; 2021; 12():756872. PubMed ID: 34975845
[TBL] [Abstract][Full Text] [Related]
35. Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.
Zeng Y; Shi Q; Liu X; Tang H; Lu B; Zhou Q; Xu Y; Chen M; Zhao J; Li Y; Qian J; Wang M; Tan B
Front Oncol; 2023; 13():1144534. PubMed ID: 37114123
[TBL] [Abstract][Full Text] [Related]
36. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
Duttagupta S; Hakozaki T; Routy B; Messaoudene M
Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
[TBL] [Abstract][Full Text] [Related]
37. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
[TBL] [Abstract][Full Text] [Related]
38. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
[TBL] [Abstract][Full Text] [Related]
39. A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Xu X; Wang D; Chen W; Li N; Suwinski R; Rossi A; Rosell R; Zhong J; Fan Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4511-4525. PubMed ID: 35070757
[TBL] [Abstract][Full Text] [Related]
40. Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.
Rolles B; Gorgulho J; Tometten M; Roderburg C; Vieri M; Abels A; Vucur M; Heymann F; Tacke F; Brümmendorf TH; Luedde T; Beier F; Loosen SH
Front Oncol; 2021; 11():729207. PubMed ID: 34490122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
